T1	intervention 116 131	bisphosphonates
T2	eligibility 512 548	women with stage I-III breast cancer
T3	No-of-participants 786 790	6018
T4	outcome 801 816	developed BRONJ
T5	outcome 818 827	Infection
T6	outcome 855 875	Median time to BRONJ
T7	outcome 957 962	BRONJ
T8	intervention-value 1004 1006	28
T9	intervention-participants 1007 1011	2231
T10	intervention-value 1013 1018	1.26%
T11	duration 623 630	3 years
T12	intervention 560 580	zoledronic acid (ZA)
T13	intervention 582 597	clodronate (CL)
T14	intervention 602 618	ibandronate (IB)
T15	intervention-value 1028 1029	8
T16	intervention-participants 1030 1034	2235
T17	intervention-value 1036 1041	0.36%
T18	intervention-value 1051 1053	12
T19	intervention-participants 1054 1058	1552
T20	intervention-value 1060 1065	0.77%
T21	outcome 1234 1262	BRONJ occurred spontaneously
